Chlorpromazine hydrochloride first became available in Europe and the United States in the early 1950s. A large, double-blind, placebo-controlled trial that was conducted within the US Veterans Affairs system and included nearly 700 patients (all men aged ≤50 years) helped establish its efficacy for treating schizophrenia.1 The use of chlorpromazine is credited with large decreases in psychiatric inpatient populations around the world, as well as prompting a widespread search for other antipsychotic drugs.
Maust DT, Kales HC. Medicating Distress. JAMA Intern Med. 2017;177(1):42–43. doi:https://doi.org/10.1001/jamainternmed.2016.7528
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: